BioSkryb Genomics key facts
- Developer of a genome amplification system designed to utilize cellular heterogeneity.
- It has raised $31.5M; the latest was Later Stage VC ($20.0M) in May 2025.
- Notable investors include Wilson Sonsini Goodrich & Rosati, Anzu Partners, Seed Healthcare.
- Status: Privately Held (backing).
Who backs BioSkryb Genomics
3- ·Watch BioSkryb Genomics: the Monday email on marks, rounds and moves
BioSkryb Genomics funding rounds
No funding rounds for BioSkryb Genomics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BioSkryb Genomics investors
3 investors are on record for BioSkryb Genomics, including Wilson Sonsini Goodrich & Rosati, Anzu Partners and Seed Healthcare.
About BioSkryb Genomics
Developer of a genome amplification system designed to utilize cellular heterogeneity. The company transforming through its single-cell whole genome and whole transcriptome amplification tools, scientists and clinicians can gain an unprecedented view of the genome, transcriptome and proteome within a single cell to understand the drivers, mechanisms and management of complex diseases and transform single-cell molecular discovery and analysis, enabling medical researchers and clinicians to elucidate the mechanisms of pathology in the genome.
- Sector
- Healthcare
- HQ
- Durham, NC, United States
- Founded
- 2018
- Employees
- 55
- Website
- bioskryb.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BioSkryb Genomics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.